Post Thu May 23, 2024 4:45 pm

2024-Van Oekelen et al-Cell Rep Med

"Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma"
Oliver Van Oekelen, Michael Amatangelo, Manman Guo, Bhaskar Upadhyaya, Adam P Cribbs, Geoffrey Kelly, Manishkumar Patel, Seunghee Kim-Schulze, Erin Flynt, Alessandro Lagana, Sarah Gooding, Miriam Merad, Sundar Jagganath, William E Pierceall, Udo Oppermann, Anjan Thakurta, Samir Parekh
Cell Rep Med. 2024

- no dataset accession given:
"The cytometry datasets used in this study are from an ongoing clinical trial of iberdomide in multiple myeloma that is sponsored by Bristol Myers Squibb (BMS). The data from this study are stored in Cytobank, an internal database at the Icahn School of Medicine at Mount Sinai, in perpetuity and are not publicly available due to patient privacy concerns and because the clinical trial is still ongoing. To request access to the data, please contact the lead contact (, and submit a request for access to This is the mailbox for BMS' Clinical Trial Transparency (CTT) organization that manages the external distribution of data generated as part of a BMS study. Upon receiving a request, the CTT reviews the request and if approved, will release the data in a properly annotated and de-identified format. The lead contact will help facilitate these requests and will connect you with a member of the CTT organization. Additional questions on submitting a request can be directed to the lead contact or to at any time and will be promptly addressed. The requestor will be required to describe the objectives of the research project for which the data will be used. Data access will be considered for research purposes and non-commercial use only. To ensure patient privacy, access to personally identifiable information or sensitive clinical information will not be provided, and requests for data access must rigorously adhere to the consent agreements established with study participants."